The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical ...
Superior efficacy at 12 weeks was seen with the frontline combination of abemaciclib and endocrine therapy vs standard ...
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) ...
4d
MEDSIR, a leading company dedicated to promoting independent clinical research in oncology internationally and part of ...
Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...
Medpage Today on MSN2d
FDA Expands Approval of Ribociclib to Early Breast CancerThe drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...
Last year, the FDA also expanded Eli Lilly’s LLY Verzenio’s (abemaciclib) indication. Verzenio, a CDK4/6 inhibitor, was ...
SurvivorNet on MSN2d
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of KisqaliThe Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...
The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved for HR-positive, HER2-negative disease, blocking cyclin-dependent kinases driving tumour growth. Immunotherapies like ...
The drug is approved in combination with an aromatase inhibitor as adjuvant therapy for breast cancer patients at high risk of recurrence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback